Heidi B. Goldfarb

Learn More
PURPOSE To evaluate the safety and efficacy of ophthalmic MIM-D3, a tyrosine kinase TrkA receptor agonist, in patients with dry eye. DESIGN A prospective, two-center, randomized, double-masked, placebo-controlled Phase 2 study. METHODS A total of 150 dry eye patients were randomized 1:1:1 to study medication (1% MIM-D3, 5% MIM-D3, or placebo) and dosed(More)
  • 1